4

$VRTX · Vertex Pharmaceuticals Incorporated

November 10, 2026 · AI-analyzed SEC filing · Verify material figures against the official SEC.gov filing

Vertex Pharmaceuticals filed a Form 4 with the SEC disclosing a stock sale by Reshma Kewalramani, the company’s CEO and President and a member of its board of directors. The filing reports that on November 6, 2026, Kewalramani sold 11,866 shares of Vertex common stock at a price of $531.53 per share.

The transaction was executed under a pre-arranged Rule 10b5-1 trading plan that Kewalramani adopted on August 5, 2026. Such plans allow company insiders to schedule trades in advance, and the filing indicates this sale was made pursuant to that plan.

Following the reported sale, Kewalramani directly beneficially owns 86,471 shares of Vertex common stock. The Form 4 is a routine regulatory filing required to report changes in beneficial ownership by corporate insiders.

Get filings like this before the market reacts.

Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.

Start your free trial →